Clinical Trial Update: Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) [Phase 1]

View source ↗

Summary

Phase 1 pilot study evaluating reparixin with weekly paclitaxel in HER2-negative metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Reparixin (reparixin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-04-19